The kynurenine pathway in chronic diseases: a compensatory mechanism or a driving force?

Area of Science:

• Biochemistry
• Neuroscience
• Immunology

Background:

• The kynurenine pathway (KP) metabolizes tryptophan (TRP) and is implicated in inflammation-driven diseases such as cancers and neurological conditions (e.g., multiple sclerosis, depression).
• Dysregulation of the KP, involving both pathological and compensatory mechanisms, is frequently observed in these diseases.
• Certain KP metabolites, like kynurenic acid (KA) and quinolinic acid (QA), have significant bioenergetic roles, potentially explaining their overactivation in disease states.

Purpose of the Study:

• To highlight the significance of the kynurenine pathway (KP) as a therapeutic target in inflammation-driven pathologies.
• To explore the dual role of KP metabolites in disease pathogenesis, encompassing both detrimental and compensatory functions.
• To emphasize the need for nuanced therapeutic strategies that consider the bioenergetic roles and metabolic balance of KP products.

Main Methods:

• Review and synthesis of existing literature on the kynurenine pathway in disease.
• Analysis of the biochemical and physiological roles of KP metabolites (KA, QA).
• Examination of disease- and tissue-specific variations in KP activation.

Main Results:

• KP dysregulation is a common feature in oncological and brain diseases, driven by complex pathological and compensatory mechanisms.
• KP metabolites, such as KA and QA, possess bioenergetic functions (e.g., QA as an NAD+ precursor) that contribute to their observed overactivation.
• Interpreting KP imbalance requires consideration of disease context, tissue specificity, inflammatory feedback, and downstream metabolite ratios.

Conclusions:

• The kynurenine pathway is a promising therapeutic target for various diseases, but its complexity must be addressed.
• Therapeutic strategies targeting the KP should account for the bioenergetic roles and compensatory functions of its metabolites.
• Future theragnostic approaches require a comprehensive understanding of KP metabolite dynamics to effectively attenuate disease progression.